NICE are inviting organisations to register as a stakeholder for the guideline: ‘Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal’.
Registered stakeholders will have the opportunity to comment on the draft scope and guideline during consultation and all comments received from registered stakeholders will be considered and responded to individually. You will also be privy to an embargoed release of the guideline prior to publication in the public domain.
To register as a stakeholder, please complete the online form from the NICE website, and you can find more information about NICE’s guideline work here.
Last year, ARMA members helped Glykeria Skamagki, the senior lecturer in Physiotherapy at Coventry University, with the first stage of a study into chronic musculoskeletal conditions and their management at the workplace. The results were very interesting and now to follow-up the researchers are conducting a survey to identify the strategies that older employees use to manage chronic musculoskeletal conditions at the workplace.
IMplementation of Physical Activity into routine Clinical pracTice in Rheumatic Musculoskeletal Disease
Rheumatoid Arthritis (RA) is very much on my mind as I write this during RA Awareness Week. Yesterday I attended a roundtable discussing the NHS Long Term Plan (LTP) and RA. Rheumatology doesn’t get a specific mention in the plan, but there is plenty of content on related issues. There is mention of chronic pain, for instance, which is very relevant to ARMA and to RA. Access to integrated pain services is something ARMA members have identified as a priority following the publication of our 
The UK Gout Society is seeking a new patient trustee.
A team of researchers and clinicians from the University of East Anglia’s School of Health Sciences and the Norfolk and Norwich University Hospitals NHS Foundation Trust are looking for contributors/partners to help in their next project. The project would involve an application for NIHR Research for Patient Benefit (tier 3) funding.
In the run up to the publication of the Government’s Green Paper on prevention, the IPPR has published a report 